Indian Pharma

Indian pharma market rises 12.1% in July on broad-based therapy growth

The market recorded sales of Rs 23,193 crore in July, with cardiac and anti-diabetic therapies posting double-digit growth and four leading segments accounting for 46.6 per cent

Indian drugmakers in no rush to shift to US despite tariff threat

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

Regulatory hurdles eclipse tariff worries for pharma CXOs: Deloitte survey

Industry seeks AI-based submission tools and unified digital portals to accelerate approvals and compliance tracking

Biocon gets Canadian health regulator's nod for Yesintek autoinjector pen

: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for

Biocon gains 3%, stock nears record high; should you buy, hold or sell?

Biocon received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia.

Indian drugmakers line up for Keytruda biosimilar race as patents near end

Biocon, Zydus, Dr Reddy's are among companies positioning for one of the largest biosimilar launches for cancer treatment

Patent expiry: A $5 bn opportunity for Indian pharma majors, says report

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

Beyond Zaynich: Wockhardt bets on WCK 6777 as next blockbuster jab

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

Cipla soars 8% despite disappointing Q4; what's driving pharma stock?

Going forward Cipla's management expects to pick up momentum in FY27 and aspires $1 billion revenue from the US itself.

India's pharma market grows 10.3% in April on strong chronic performance

India's pharmaceutical market grew 10.3 per cent in April, led by strong demand for anti-diabetes, cardiac and respiratory therapies

Lack of growth visibility at Organon could cap Sun Pharma's gains

Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential

Cohance Lifesciences appoints Umang Vohra as chairman, CEO; Sharma exits

Pharma veteran Umang Vohra to lead Advent-backed Cohance Lifesciences as chairman and CEO, succeeding Vivek Sharma amid efforts to revive growth and address regulatory challenges

Rubicon Research sharpens India play with focus on CNS: CEO Parag Sancheti

Currently, more than 95 per cent of Rubicon's revenue comes from the United States (US), where the company has built a generics and specialty portfolio

Lupin eyes next US growth pillar in complex generics and biosimilars

Nearly six decades after its founding, Lupin is targeting its next global growth phase in the US with a strategy centred on complex generics, biosimilars and innovation

India, Uzbekistan launch pharma-nutra corridor; focus on Eurasian market

India and Uzbekistan have launched a policy-backed pharma-nutraceutical corridor to improve regulatory alignment, investment and market access for manufacturers targeting the $7-10 billion Eurasian he

Indian pharma market grows 11% in Feb as Mounjaro tops drug sales

The Indian pharmaceutical market posted 11% growth in February 2026, driven by strong therapy performance, while Mounjaro remained India's highest-selling drug by value for a fifth month

MNCs, Indian drugmakers diverge to mutual gain: How win-win is it?

Novartis exits India's mass-market generics, signalling a deeper split between MNC innovation bets and domestic pharma scale

Lupin gains 2%, hits 52-week high; why pharma stock in focus?

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

AI, trust and faster innovation bets to shape India's pharma future by 2047

At the IPA summit, pharma leaders said India's 2047 ambitions depend on embedding AI, strengthening trust and accelerating innovation, as speed and quality become the sector's defining advantages

India's drugmakers show fewer side effects under harsher USFDA scrutiny

USFDA data show OAI rates for Indian pharma plants falling to 8% by 2025 even as global outcomes worsen, reflecting stronger quality systems, technology adoption and compliance culture